BR112016018077A8 - inibidor de proteína de transferência de éster colesterílico (composto a), composições farmacêuticas compreendendo o mesmo, método para preparação das referidas composições e uso do composto a - Google Patents
inibidor de proteína de transferência de éster colesterílico (composto a), composições farmacêuticas compreendendo o mesmo, método para preparação das referidas composições e uso do composto a Download PDFInfo
- Publication number
- BR112016018077A8 BR112016018077A8 BR112016018077A BR112016018077A BR112016018077A8 BR 112016018077 A8 BR112016018077 A8 BR 112016018077A8 BR 112016018077 A BR112016018077 A BR 112016018077A BR 112016018077 A BR112016018077 A BR 112016018077A BR 112016018077 A8 BR112016018077 A8 BR 112016018077A8
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- compositions
- same
- transfer protein
- cholesteryl ester
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 title abstract 3
- 229940125881 cholesteryl ester transfer protein inhibitor Drugs 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 2
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
inibidor de proteína de transferência de éster colesterílico (composto a), composições farmacêuticas compreendendo o mesmo e uso do composto a a presente invenção refere-se a um inibidor da proteína de transferência de éster colesterílico (cetp): (aqui referido como composto a) ou um sal farmaceuticamente aceitável do mesmo para utilização no tratamento de indivíduos que sofrem de ou que têm um risco aumentado de doenças cardiovasculares, em especial da hiperlipidemia ou dislipidemia mista. outro aspecto da presente invenção refere-se a uma composição farmacêutica para utilização no tratamento de indivíduos que sofrem de ou que têm um risco aumentado de doenças cardiovasculares, em que a composição compreende uma quantidade terapeuticamente eficaz do referido inibidor de cetp do composto a.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/NL2014/050068 WO2015119495A1 (en) | 2014-02-05 | 2014-02-05 | Cholesteryl ester transfer protein (cetp) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112016018077A2 BR112016018077A2 (pt) | 2017-08-08 |
| BR112016018077A8 true BR112016018077A8 (pt) | 2020-06-23 |
Family
ID=50116144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016018077A BR112016018077A8 (pt) | 2014-02-05 | 2014-02-05 | inibidor de proteína de transferência de éster colesterílico (composto a), composições farmacêuticas compreendendo o mesmo, método para preparação das referidas composições e uso do composto a |
Country Status (32)
| Country | Link |
|---|---|
| US (4) | US10653692B2 (pt) |
| EP (1) | EP3102212B1 (pt) |
| JP (1) | JP6263271B2 (pt) |
| KR (1) | KR101967970B1 (pt) |
| CN (5) | CN113332287A (pt) |
| AP (1) | AP2016009359A0 (pt) |
| AR (1) | AR099299A1 (pt) |
| AU (1) | AU2014381733B2 (pt) |
| BR (1) | BR112016018077A8 (pt) |
| CA (1) | CA2938718C (pt) |
| CR (1) | CR20160353A (pt) |
| CY (1) | CY1121707T1 (pt) |
| DK (1) | DK3102212T3 (pt) |
| EA (1) | EA032689B1 (pt) |
| ES (1) | ES2710104T3 (pt) |
| HR (1) | HRP20190211T1 (pt) |
| HU (1) | HUE042932T2 (pt) |
| IL (1) | IL247037A (pt) |
| LT (1) | LT3102212T (pt) |
| MA (1) | MA39319A1 (pt) |
| ME (1) | ME03295B (pt) |
| MX (1) | MX369471B (pt) |
| PH (1) | PH12016501548A1 (pt) |
| PL (1) | PL3102212T3 (pt) |
| PT (1) | PT3102212T (pt) |
| RS (1) | RS58329B1 (pt) |
| SG (1) | SG11201605956RA (pt) |
| SI (1) | SI3102212T1 (pt) |
| TW (1) | TWI651086B (pt) |
| UA (1) | UA120922C2 (pt) |
| WO (1) | WO2015119495A1 (pt) |
| ZA (1) | ZA201605490B (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA120922C2 (uk) * | 2014-02-05 | 2020-03-10 | Дезима Фарма Б.В. | Інгібітор білка-переносника ефіру холестерину (cetp) і фармацевтичні композиції, які містять вказаний інгібітор, для застосування в лікуванні або запобіганні серцево-судинним захворюванням |
| US10300059B2 (en) * | 2014-08-28 | 2019-05-28 | Dezima Pharma B.V. | Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and HMG CoA reductase inhibitors |
| JP2024507810A (ja) * | 2021-02-18 | 2024-02-21 | ニューアムステルダム・ファルマ・ベー・フェー | 高脂血症又は混合型脂質異常症に罹患しているスタチン不耐性患者における使用のためのオビセトラピブ及びエゼチミブの併用療法 |
| IL305576A (en) * | 2021-03-05 | 2023-10-01 | Newamsterdam Pharma B V | Objetive for the treatment of dementia |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA90269C2 (ru) * | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Тетрагидрохинолиновые производные и способ их получения |
| EA200700119A1 (ru) * | 2004-06-24 | 2007-10-26 | Эли Лилли Энд Компани | Соединения и способы лечения дислипидемии |
| CN101098690A (zh) * | 2004-12-06 | 2008-01-02 | 瑞莱恩特医药品有限公司 | 用于血脂治疗的ω-3脂肪酸和脂血异常剂 |
| JP4531027B2 (ja) * | 2005-09-29 | 2010-08-25 | 田辺三菱製薬株式会社 | 医薬組成物 |
| CN101553221A (zh) * | 2006-10-10 | 2009-10-07 | 瑞莱恩特医药品有限公司 | 用于降低APO-B水平的抑制素和ω-3脂肪酸 |
| JO3210B1 (ar) | 2011-10-28 | 2018-03-08 | Merck Sharp & Dohme | مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة |
| UA120922C2 (uk) | 2014-02-05 | 2020-03-10 | Дезима Фарма Б.В. | Інгібітор білка-переносника ефіру холестерину (cetp) і фармацевтичні композиції, які містять вказаний інгібітор, для застосування в лікуванні або запобіганні серцево-судинним захворюванням |
| US10300059B2 (en) * | 2014-08-28 | 2019-05-28 | Dezima Pharma B.V. | Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and HMG CoA reductase inhibitors |
-
2014
- 2014-02-05 UA UAA201609188A patent/UA120922C2/uk unknown
- 2014-02-05 ME MEP-2019-27A patent/ME03295B/me unknown
- 2014-02-05 EA EA201691572A patent/EA032689B1/ru not_active IP Right Cessation
- 2014-02-05 CA CA2938718A patent/CA2938718C/en active Active
- 2014-02-05 ES ES14705225T patent/ES2710104T3/es active Active
- 2014-02-05 MA MA39319A patent/MA39319A1/fr unknown
- 2014-02-05 EP EP14705225.2A patent/EP3102212B1/en active Active
- 2014-02-05 WO PCT/NL2014/050068 patent/WO2015119495A1/en active Application Filing
- 2014-02-05 CN CN202110492572.6A patent/CN113332287A/zh active Pending
- 2014-02-05 SI SI201431043T patent/SI3102212T1/sl unknown
- 2014-02-05 AU AU2014381733A patent/AU2014381733B2/en active Active
- 2014-02-05 RS RS20190122A patent/RS58329B1/sr unknown
- 2014-02-05 CN CN201480074940.3A patent/CN106232121A/zh active Pending
- 2014-02-05 SG SG11201605956RA patent/SG11201605956RA/en unknown
- 2014-02-05 BR BR112016018077A patent/BR112016018077A8/pt not_active Application Discontinuation
- 2014-02-05 CN CN202110492605.7A patent/CN113332288A/zh active Pending
- 2014-02-05 LT LTEP14705225.2T patent/LT3102212T/lt unknown
- 2014-02-05 JP JP2016550780A patent/JP6263271B2/ja active Active
- 2014-02-05 AP AP2016009359A patent/AP2016009359A0/en unknown
- 2014-02-05 PT PT14705225T patent/PT3102212T/pt unknown
- 2014-02-05 DK DK14705225.2T patent/DK3102212T3/en active
- 2014-02-05 MX MX2016010212A patent/MX369471B/es active IP Right Grant
- 2014-02-05 CN CN201911087834.XA patent/CN110721187A/zh active Pending
- 2014-02-05 US US15/117,154 patent/US10653692B2/en active Active
- 2014-02-05 HU HUE14705225A patent/HUE042932T2/hu unknown
- 2014-02-05 CN CN202011468410.0A patent/CN112755031A/zh active Pending
- 2014-02-05 PL PL14705225T patent/PL3102212T3/pl unknown
- 2014-02-05 CR CR20160353A patent/CR20160353A/es unknown
- 2014-02-05 KR KR1020167024380A patent/KR101967970B1/ko active IP Right Grant
-
2015
- 2015-02-04 TW TW104103678A patent/TWI651086B/zh active
- 2015-02-05 AR ARP150100338A patent/AR099299A1/es unknown
-
2016
- 2016-08-01 IL IL247037A patent/IL247037A/en active IP Right Grant
- 2016-08-04 PH PH12016501548A patent/PH12016501548A1/en unknown
- 2016-08-08 ZA ZA2016/05490A patent/ZA201605490B/en unknown
-
2019
- 2019-01-17 CY CY20191100064T patent/CY1121707T1/el unknown
- 2019-01-31 HR HRP20190211TT patent/HRP20190211T1/hr unknown
-
2020
- 2020-04-09 US US16/844,996 patent/US11013742B2/en active Active
-
2021
- 2021-04-09 US US17/226,655 patent/US11642344B2/en active Active
-
2023
- 2023-04-03 US US18/130,178 patent/US20240024315A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2018000104A2 (es) | Moléculas de anticuerpo que se unen a cd22 | |
| EA201792047A1 (ru) | Новые соединения | |
| MX2022003891A (es) | Anticuerpos anti-muc16 y sus usos. | |
| CO2018000410A2 (es) | Moléculas de anticuerpo que se unen a cd79 | |
| EA201790528A1 (ru) | Дигидропирролопиридиновые ингибиторы ror-гамма | |
| CL2014001547A1 (es) | Compuestos derivados de benzotienilo-pirrolotriazina, como inhibidores de la proteina tirosina quinasa; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para el tratamiento y/o la prevencion de cancer y enfermedades tumorales. | |
| BR112016017041A2 (pt) | Proteína isolada tendo atividade de fosfatase, polinucleotídeo, vetor, célula hospedeira, método para produzir uma proteína e composição | |
| BR112015029969A2 (pt) | tratamento de câncer usando moduladores de isoformas quinase pi3 | |
| BR112018000212A2 (pt) | uso combinado de anticorpos anti pd-1 e anti m-csf no tratamento de câncer | |
| EA201690159A1 (ru) | Способы и композиции для лечения рака | |
| BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
| BR112018005905A2 (pt) | ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto? | |
| BR112017026535A2 (pt) | composto de fórmula estrutural i, enantiômero isolado, composição farmacêutica, método para inibir atividade do transportador de monocarboxilato mct4, método para inibir seletivamente atividade do transportador de monocarboxilato mct4, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 e uso de um composto | |
| BR112017004173A2 (pt) | composto, composição farmacêutica, e, método para tratar uma doença ou condição patológica. | |
| EA201690039A1 (ru) | Ингибиторы rorc2 и способы их применения | |
| BR112016003584A8 (pt) | composições farmaceuticas e uso das mesmas para regressão de placa acelerada | |
| CO2016000671A1 (es) | Construcciones de variantes de sirp-alfa y sus usos | |
| EP3328864A4 (en) | COMPOUNDS AND THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF SOCIAL DISORDERS AND ADDICTION-RELATED DISORDERS | |
| BR112017019358A2 (pt) | combinações e formulações de dose fixa compreendendo etc1002 e ezetimiba e métodos de tratamento ou redução do risco de doença cardiovascular | |
| NZ735777A (en) | Methods and compositions to inhibit symptoms associated with veisalgia | |
| BR112017018198A2 (pt) | inibição da atividade de olig2 | |
| CY1121707T1 (el) | Αναστολεας πρωτεϊνης μεταφορας εστερων χοληστερολης (cetp) και φαρμακευτικες συνθεσεις που περιλαμβανουν τον εν λογω αναστολεα για χρηση στη θεραπεια ή την προληψη καρδιαγγειακων νοσηματων | |
| BR112016023011A2 (pt) | tratamento de câncer gástrico | |
| EA201690302A1 (ru) | Композиции для местного применения для лечения избыточного потоотделения и способы их применения | |
| EA201792445A1 (ru) | Новые амидогетероарилароилгидразидэтины |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: DEZIMA PHARMA B.V. (NL) |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
| B25D | Requested change of name of applicant approved |
Owner name: NEWAMSTERDAM PHARMA B.V. (NL) |